Business
Theravance Biopharma Appoints Andrew Hindman as Senior Vice President and Chief Financial Officer
DUBLIN, June 4, 2019 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company") today announced the appointment of
About this update from Theravance Biopharma, Inc.
[{"type":"text","content":"DUBLIN, June 4, 2019 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) (\"Theravance Biopharma\" or the \"Company\") today announced the appointment of Andrew Hindman as Senior Vice President and Chief Financial Officer. Mr. Hindman brings nearly 25 years of life science industry experience spanning a broad range of functional areas including corporate strategy, finance, business development, operations, public policy and marketing. Importantly, he possesses broad therapeutic expertise and has established a strong track record of long-term value creation at several high-profile life science companies including Gilead Sciences, Acorda Therapeutics and Onyx Pharmaceuticals. \n\n \n\"Theravance Biopharma has built one of the industry's most promising portfolios of commercial products and development-stage programs, with a unique focus on organ-selective drugs that offer the potential for localized therapeutic impact without systemic exposure and related toxicities. With these high-value assets positioning the Company for near and long-term success, I am excited to join the team and contribute to efforts to maximize shareholder value,\" said Mr. Hindman. \"I share the Company's commitment to developing medicines that make a difference in the lives of patients and look forward to working to continue the Company's pursuit of this important goal.\" \n\"Andrew's wide-ranging experience across critical functional areas, combined with his strong track record of driving significant value creation at several well-known life science companies, make him a valuable addition to the Theravance Biopharma team,\" said Rick E Winningham, Chairman and Chief Executive Officer of Theravance Biopharma. \"In addition to his impressive professional experience, Andrew's reputation for high energy and collaboration clearly distinguished him during our CFO search and positions him as an excellent fit for our corporate culture. We're excited to welcome Andrew to the Theravance Biopharma team and look forward to the key contributions he will make to the Company's ongoing success.\"\nMr. Hindman has held several senior executive level positions in the biopharmaceutical industry, most recently as Chief Business Officer of Acorda Therapeutics. In this role, he led Acorda's acquisitions of Civitas Therapeutics and Biotie Therapies, helping transform the b...